Serologic evidence of seasonal influenza A and B in HIV patients on combined antiretroviral therapy in Lagos, Nigeria

African Journal of Laboratory Medicine


 
 
Field Value
 
Title Serologic evidence of seasonal influenza A and B in HIV patients on combined antiretroviral therapy in Lagos, Nigeria
 
Creator Anjorin, AbdulAzeez A. Adepoju, Barakat A.
 
Subject Respiratory tract virology; Influenza virology; medical virology influenza A; influenza B; HIV co-infection; seroprevalence; Lagos
Description Background: Influenza and HIV are endemic in Nigeria but there is no epidemiological data on the co-infection of influenza A and B among HIV patients.Objective: We investigated seasonal influenza A and B, and co-infection among HIV patients on combined antiretroviral therapy (cART) in Lagos, Nigeria.Methods: In a prospective cross-sectional study, clear sera collected from 174 HIV-positive patients between August and September 2018 were analysed for immunoglobulin M-specific antibodies to seasonal influenza A subtypes H1N1 and H3N2, and influenza B by enzyme immunoassay.Results: A total of 39.7% (69/174) of HIV patients were seropositive for influenza A or B viruses with 84.1% (58/69) being positive for influenza A, 13.04% (9/69) seropositive for both influenza A and B, and only 2.9% (2/69) positive for influenza B mono-infection. Median age was 44 (mean 45, mode 40, range 18–74) years. The 41–50 years age group had the highest seroprevalence (39.1%; 27/69). Seropositivity was highest among women (65.2%; 45/69). A total of 88.4% (61/69) of HIV patients seropositive for influenza A or B were on fixed dose cART, while 73.9% (51/69) were virologically suppressed. Furthermore, 27.5% (19/69) were immunocompromised, of which 21.1% (4/19) were severely immunosuppressed (cluster of differentiation 4 200 cells/mm3).Conclusion: Influenza A and B was prevalent among HIV patients on cART, which may predispose them to life-threatening complications. We recommend strong advocacy on the need to reduce the risk of exposure to influenza and for the provision of an influenza vaccine in Nigeria.
 
Publisher AOSIS
 
Contributor
Date 2020-12-21
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Cross-sectional
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/ajlm.v9i1.1048
 
Source African Journal of Laboratory Medicine; Vol 9, No 1 (2020); 6 pages 2225-2010 2225-2002
 
Language eng
 
Relation https://ajlmonline.org/index.php/ajlm/article/view/1048/1828 https://ajlmonline.org/index.php/ajlm/article/view/1048/1827 https://ajlmonline.org/index.php/ajlm/article/view/1048/1829 https://ajlmonline.org/index.php/ajlm/article/view/1048/1826
 
Coverage Lagos — HIV patients; Male; Female
Rights Copyright (c) 2020 AbdulAzeez A. Anjorin, Barakat A. Adepoju https://creativecommons.org/licenses/by/4.0